Policy & Regulation
Treadwell Announces Starts Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer
13 August 2020 - - The Canadian Cancer Trials Group have started a phase 2 study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer, the group said.

This multi-center, single-arm, open-label phase 2 trial is designed to assess the efficacy of CFI-400945 given with durvalumab in patients with treatment-resistant TNBC.

The primary endpoint is objective response rate. Secondary endpoints include disease control rate, immune-related response rate, safety and tolerability, and correlative studies, including cfDNA analyses.

Initially, participating centers will include the PMCC, the Ottawa Hospital Research Institute, and Kingston Health Sciences Centre.

CFI-400945 is a first-in-class, oral selective and potent inhibitor of Polo-like Kinase 4, which regulates centriole duplication and thus mitotic progression.

PLK4 is overexpressed in a variety of solid tumors and elevated expression is associated with poor clinical outcomes.

Depletion of PLK4 expression in cancer cells by RNA interference leads to mitotic defects and cell death. PLK4 was identified as a drug target based on functional screening to identify vulnerabilities of genomically unstable breast cancers.

Anti-tumor activity of CFI-400945 has been shown in mice bearing human cancer xenografts, including robust tumor growth inhibition and durable tumor regression in primary tumor xenografts from breast cancer.

Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells' vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer.

The company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best in class TTK inhibitor, CFI-402257 in Phase 2 studies, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1, in Phase 1/2 studies.

Celebrating its 40th year, the Canadian Cancer Trials Group is a cancer clinical trials research cooperative that runs phase I-III trials to test anti-cancer and supportive therapies in over 80 institutions across Canada and internationally.

From its operations centre at Queen's University, CCTG has led and participated in over 500 trials in over 40 countries aimed at improving survival and quality of life for all people with cancer.

CCTG is a national program of the Canadian Cancer Society that provides core funding for the group.